Getagraph.com logo
NASDAQ Composite: ( -0.07%) 16 686
S&P 500
(0.12%) 5 303.27 points
Dow Jones
(0.34%) 40 004 points
Nasdaq
(-0.07%) 16 686 points
Oil
(-0.07%) $80.00
Gas
(0.46%) $2.64
Gold
(0.10%) $2 419.80
Silver
(1.65%) $31.78
Platinum
(0.43%) $1 094.70
USD/EUR
(-0.03%) $0.920
USD/NOK
(-0.01%) $10.69
USD/GBP
(-0.19%) $0.788
USD/RUB
(0.02%) $90.89

Realaus laiko atnaujinimai Leap Therapeutics Inc [LPTX]

Birža: NASDAQ Sektorius: Healthcare Pramonė: Biotechnology
Upcoming Earnings Alert

Quarter results tomorrow
(bmo 2024-05-20)

Expected move: +/- 14.57%

BUY
100.00%
return 10.47%
SELL
0.00%
return 11.12%
Atnaujinta17 geg. 2024 @ 23:00
25% discount on Stockinvest.us - Use code: Podcast

-4.01% $ 2.63

PARDAVIMAS 145502 min ago

@ $3.52

Išleistas: 8 vas. 2024 @ 21:59

Grąža: -25.28%

Ankstesnis signalas: vas. 7 - 22:44

Ankstesnis signalas: Pirkimas

Grąža: 2.03 %

Live Chart Being Loaded With Signals

Commentary (17 geg. 2024 @ 23:00):

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers...

Stats
Šios dienos apimtis 375 785
Vidutinė apimtis 307 798
Rinkos kapitalizacija 100.64M
EPS $0 ( 2024-05-13 )
Kita pelno data ( $-0.570 ) 2024-05-20
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -0.660
ATR14 $0.0230 (0.87%)
Insider Trading
Date Person Action Amount type
2024-04-10 Gilead Sciences, Inc. Sell 0 Common Stock
2024-01-29 Mashiach Nissim Buy 25 000 Stock Option (Right to Buy)
2024-01-29 Dietz Thomas John Buy 30 000 Stock Option (Right to Buy)
2024-01-29 Schilsky Richard Buy 25 000 Stock Option (Right to Buy)
2024-01-29 Granfield Christine Buy 85 000 Employee Stock Option (Right to Buy)
INSIDER POWER
66.43
Last 95 transactions
Buy: 10 825 606 | Sell: 1 768 106

Tūris Koreliacija

Ilgas: 0.14 (neutral)
Trumpas: -0.76 (moderate negative)
Signal:(53.092) Neutral

Leap Therapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
AUR0.84
MYNA0.812
ANGO0.807
RELL0.806
10 Labiausiai neigiamai susiję koreliacijos
KROS-0.851
PPH-0.836
REGN-0.815

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Leap Therapeutics Inc Koreliacija - Valiuta/Žaliavos

The country flag 0.52
( weak )
The country flag 0.44
( neutral )
The country flag 0.00
( neutral )
The country flag 0.61
( weak )
The country flag 0.29
( neutral )
The country flag 0.47
( neutral )

Leap Therapeutics Inc Finansinės ataskaitos

Annual 2023
Pajamos: $0
Bruto pelnas: $-427 000 (0.00 %)
EPS: $-3.98
FY 2023
Pajamos: $0
Bruto pelnas: $-427 000 (0.00 %)
EPS: $-3.98
FY 2022
Pajamos: $0
Bruto pelnas: $-415 000 (0.00 %)
EPS: $-4.82
FY 2021
Pajamos: $1.50M
Bruto pelnas: $1.50M (100.00 %)
EPS: $-0.470

Financial Reports:

No articles found.

Leap Therapeutics Inc Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Leap Therapeutics Inc

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Apie Signalai gyvai

Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.

Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.